| People | Locations | Statistics |
|---|---|---|
| Naji, M. |
| |
| Motta, Antonella |
| |
| Aletan, Dirar |
| |
| Mohamed, Tarek |
| |
| Ertürk, Emre |
| |
| Taccardi, Nicola |
| |
| Kononenko, Denys |
| |
| Petrov, R. H. | Madrid |
|
| Alshaaer, Mazen | Brussels |
|
| Bih, L. |
| |
| Casati, R. |
| |
| Muller, Hermance |
| |
| Kočí, Jan | Prague |
|
| Šuljagić, Marija |
| |
| Kalteremidou, Kalliopi-Artemi | Brussels |
|
| Azam, Siraj |
| |
| Ospanova, Alyiya |
| |
| Blanpain, Bart |
| |
| Ali, M. A. |
| |
| Popa, V. |
| |
| Rančić, M. |
| |
| Ollier, Nadège |
| |
| Azevedo, Nuno Monteiro |
| |
| Landes, Michael |
| |
| Rignanese, Gian-Marco |
|
Ionov, Maksim
in Cooperation with on an Cooperation-Score of 37%
Topics
Publications (18/18 displayed)
- 2023Ruthenium metallodendrimer against triple-negative breast cancer in micecitations
- 2023Combination of Copper Metallodendrimers with Conventional Antitumor Drugs to Combat Cancer in In Vitro Modelscitations
- 2023Combination of Copper Metallodendrimers with Conventional Antitumor Drugs to Combat Cancer in In Vitro Models
- 2023Lipid-coated ruthenium dendrimer conjugated with doxorubicin in anti-cancer drug delivery: Introducing protocolscitations
- 2023Lipid-coated ruthenium dendrimer conjugated with doxorubicin in anti-cancer drug delivery: Introducing protocolscitations
- 2023Carbosilane ruthenium metallodendrimer as alternative anti-cancer drug carrier in triple negative breast cancer mouse model: A preliminary studycitations
- 2022Heterofunctionalized polyphenolic dendrimers decorated with caffeic acid: Synthesis, characterization and antioxidant activitycitations
- 2021Organometallic dendrimers based on Ruthenium(II) N-heterocyclic carbenes and their implication as delivery systems of anticancer small interfering RNAcitations
- 2020Copper (II) Metallodendrimers Combined with Pro-Apoptotic siRNAs as a Promising Strategy Against Breast Cancer Cellscitations
- 2020Copper (II) metallodendrimers combined with pro- apaoptotic siRNAs as a promising strategy against breast cancer cellscitations
- 2019Immunoreactivity changes of human serum albumin and alpha-1-microglobulin induced by their interaction with dendrimerscitations
- 2019Dendrimers and hyperbranched structures for biomedical applicationscitations
- 2019Synthesis and Characterization of FITC Labelled Ruthenium Dendrimer as a Prospective Anticancer Drugcitations
- 2019Dendrimer for Templating the Growth of Porous Catechol-Coordinated Titanium Dioxide Frameworks: Toward Hemocompatible Nanomaterialscitations
- 2018Ruthenium dendrimers as carriers for anticancer siRNAcitations
- 2015Anticancer siRNA cocktails as a novel tool to treat cancer cells. Part (B). Efficiency of pharmacological actioncitations
- 2015Anticancer siRNA cocktails as a novel tool to treat cancer cells. Part (A). Mechanisms of interactioncitations
- 2013Natural and Synthetic Biomaterials as Composites of Advanced Drug Delivery Nano Systems (ADDNSS). Biomedical Applicationscitations
Places of action
| Organizations | Location | People |
|---|
booksection
Natural and Synthetic Biomaterials as Composites of Advanced Drug Delivery Nano Systems (ADDNSS). Biomedical Applications
Abstract
The combination of natural and synthetic biomaterials leads to the formation of advanced Drug Delivery nano Systems (aDDnSs). The aDDnSs can be classified as hybridic (hy‐) or chimeric (chi‐) based on the nature – same or different respectively ‐ of biomaterials used. Such advanced bio complexes can alter the pharmacokinetic properties of the encapsulated drug and consequently its effectiveness. Numerous studies regarding the usage of natural or synthetic biomaterials as drug carriers have been performed, while only few studies concerning the combination of different kinds of biomaterials have been published. Carriers produced by the combination of liposomes and dendrimers were recently characterized as chi‐aDDnSs belonging to the class of Modulatory Liposomal Controlled Released Systems (MLCRSs) where the polymeric or the dendritic component act as modulator of the drug's release from the carrier. A small but significant number of studies have begun to shed light on the interactions between the components of the bio complexes that seem to be of utmost importance for the pharmacological effectiveness of the final formulation. This review deals with the categorization of the aDDnSs, the nature of the interacting forces between them and their potential biomedical applications.